Machine learning for predicting the response of breast cancer to neoadjuvant chemotherapy

Abstract

Predictive modeling approaches based on machine learning using readily available clinical and quantitative MRI data show promise in distinguishing breast cancer responders from non-responders after the first cycle of NAC.